CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 37-48 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy.

Jordana-Urriza L; Muraro MG; Du M; Lambrecht V; Rodriguez-Madoz JR; Martin I; García-García A

2026PubMedDirectly related

Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products.

Blumenberg V; June KB; Birocchi F; Escobar G; Graham C; Fan Y; Phillips MK; Park S; Harris D; Anderson H; Bouffard AA; Kelly C; Elsallab M; Berger TR; Gallagher KM; Leick MB; Mucci A; Maus MV

Jan 1, 2026Journal for immunotherapy of cancer

2026PubMedDirectly related

Quantitative Characterization of Innate and Adaptive Pharmacology of Allogeneic anti-CD20 Chimeric Antigen Receptor (CAR) Vδ1 γδ T cells using Multiscale Mechanistic Modeling.

Desai DA; Elashkar O; Cristofoletti R; Mugundu G; Singh AP

Jan 1, 2026The AAPS journal

2026PubMedDirectly related

Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers.

Manriquez-Roman C; Siegler EL; Gleba JJ; Huynh TN; DeFranco GE; Demirer AA; Pawlush ML; Redig M; Klinge SM; Mai LK; Miller JL; Miller EE; Kimball BL; Tapper EE; Sakemura RL; Stewart CM; Can I; Sirpilla OL; Feigin JM; Yun K; Gutierrez-Ruiz OL; Xia H; Hefazi M; Schick KJ; Ogbodo EJ; Olivier G; Qiu Y; Smallridge RC; Zubair A; Tun HW; Copland JA; Kenderian SS

Jan 1, 2026Molecular cancer

2026PubMedDirectly related

T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.

Zhao J; Bangolo A; Zhang L; Gutierrez M; Gonzalez-Velez M

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment.

Suarez-Trujillo F; Steiner TS; Gisbert JP; Chaparro M

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Optimizing the Hinge Length of Chimeric Antigen Receptor with a DdFP-Based Immunological Synapse Biosensor.

Jo H; Lee SE; Lee HN; Hong J; Lee CH; Kim HR; Seong J

Jan 1, 2026ACS sensors

2026PubMedDirectly related

Cord Blood-Derived Fibroblast Activation Protein-Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo.

Hiroshima T; Kimura T; Maekawa M; Noguchi M; Matsui T; Ikeda S; Suga M; Nagata H; Kimura K; Fukui E; Kanou T; Ose N; Morii E; Shintani Y; Hosen N

Jan 1, 2026Cancer science

2026PubMedDirectly related

In vivo CAR T-cell generation: delivery platforms, clinical progress, and translational barriers.

Huo T; Yao H; Kong Z

Jan 1, 2026Frontiers in immunology

2026PubMedDirectly related

Oncofetal antigens as emerging targets in chimeric antigen receptor (CAR)-T cell-based immunotherapies: opportunities and challenges.

Smith SS; Klampatsa A

Jan 1, 2026Frontiers in cell and developmental biology

2026PubMedDirectly related

Expert assessment of the attributes of high-cost medications: a case study of CAR T-cell therapy in the gulf cooperation council.

AlRuthia Y; Al Dallal S; Hamad A; Al Khalifa ME; Al-Sabahi S; Wani S; Alibrahim A; Alharbi I; Alhenaidi A; Almari M; Aloumi A; Aljalahma M

Jan 1, 2026Frontiers in pharmacology

2026PubMedDirectly related

TSPAN32 enhances CAR-T cell potency by assembling IL-2 receptor complex and amplifying its intracellular signal transduction.

Sun Y; Qiu Q; Wang B; Feng Y; Wang J; Pan C; Zheng L; Qiu H; He W; Su Z; Li S; Hu Y

Jan 1, 2026British journal of cancer